FDA approves a Labcorp test to help identify patients with advanced melanoma
Labcorp reported Q3 2026 revenue of $3.81 billion, up 6.9% YoY, and adjusted EPS of $4.78, up 14.5%. The company raised full-year guidance, targeting 5.9% to 6.7% revenue growth and $18.30 to $18.70 adjusted EPS. Labcorp received FDA approval for a melanoma diagnostic test and announced several acquisitions and partnerships, including deals with BioReference Health, Myriad Genetics, and Millennium Health.
How this was made
The 30-second read
Why it matters
The earnings beat and FDA approval together provide a clear catalyst for short‑term price appreciation.
Market read
A large‑cap healthcare stock with fresh earnings and regulatory news, offering a timely trading opportunity.
What to watch
Potential integration challenges from recent acquisitions could temper near‑term earnings growth.
Background
Labcorp disclosed Q3 2026 results and announced several strategic acquisitions and collaborations, highlighting its growth strategy.
Ticker impact
Labcorp received FDA approval for its PGDx elio® tissue complete CDx test for advanced melanoma and reported Q3 2026 earnings with revenue and EPS growth.
likely upward pressure as market prices in the earnings beat and new diagnostic approval
Both earnings beat and a new FDA‑cleared companion diagnostic are fresh, material news for a large‑cap lab services company.
Market effects
Strengthens outlook for the clinical diagnostics sector and may lift peers with similar test portfolios.
U.S. healthcare and biotech markets could see modest gains.
Adds to global momentum for FDA‑approved oncology diagnostics.
Counterpoint
If the market has already priced in the earnings beat, the FDA approval may be a modest catalyst, limiting upside.
Key entities
- companyLabcorp Holdings Inc.
U.S. clinical laboratory services provider.
- companyPGDx
Partner providing the elio® tissue complete CDx test.
